Showing results (1-10 of 7) with videos related to

Sort By:
Pageof 1
Current Radiopharmaceuticals|December 29, 2011
The ARRONAX projectFerid Haddad, Jacques Barbet, Jean-Francois Chatal
Journal of Cancer Research and Therapeutics|December 17, 2009
Different ways to improve the clinical effectiveness of radioimmunotherapy in solid tumorsJean-Francois Chatal, Francois Davodeau, Michel Cherel, et al.
Update on Cancer Therapeutics|March 4, 2008
Cancer Imaging and Therapy with Bispecific Antibody PretargetingDavid M Goldenberg, Jean-Francois Chatal, Jacques Barbet, et al.
Frontiers in Oncology|June 27, 2013
Improvement of radioimmunotherapy using pretargetingEric Frampas, Caroline Rousseau, Caroline Bodet-Milin, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 6, 2005
Mechanisms of cell sensitization to alpha radioimmunotherapy by doxorubicin or paclitaxel in multiple myeloma cell linesStephane Supiot, Sebastien Gouard, Josiane Charrier, et al.
Journal of Drug Targeting|December 29, 2004
A new bifunctional chelating agent conjugated with monoclonal antibody and labelled with technetium-99m for targeted scintigraphy: 6-(4-isothiocyanatobenzyl)-5,7-dioxo-1,11-(carboxymethyl)-1,4,8,11-tetraazacyclotridecaneAnil Kumar Mishra, Puja Panwar, Makoto Hosono, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 14, 2010
High rates of durable responses with anti-CD22 fractionated radioimmunotherapy: results of a multicenter, phase I/II study in non-Hodgkin's lymphomaFranck Morschhauser, Françoise Kraeber-Bodéré, William A Wegener, et al.
Pageof 1